Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference
Impel NeuroPharma will present a corporate overview at the Raymond James Human Health Innovations Conference on June 23, 2021, at 3:20 p.m. ET. The company is dedicated to developing therapies for central nervous system diseases with high unmet needs. Their pipeline includes products like TRUDHESA™ for migraines and INP105 for autism-related agitation. A live webcast of the presentation will be available on their website, with an archived version accessible shortly after the event.
- None.
- None.
Insights
Analyzing...
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that the Company will present a corporate overview at the Raymond James Human Health Innovations Conference on Wednesday, June 23, 2021 at 3:20 p.m. ET.
A live webcast, if recorded, of the presentation can be accessed under “News & Events” in the Investors section of the Company’s website at https://investors.impelnp.com/investor-relations. The archived webcast will be available on the Company’s website shortly after the event.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Contact
Investor Relations:
Christina Tartaglia
Stern Investor Relations
Phone: (1) 212-362-1200
Email: christina.tartaglia@sternir.com
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com
FAQ
What is the date and time of Impel NeuroPharma's presentation at the Raymond James Conference?
Where can I watch the live webcast of Impel NeuroPharma's presentation?
What therapies is Impel NeuroPharma developing for CNS diseases?
What focus areas does Impel NeuroPharma target with its product candidates?
Will there be an archived version of the webcast after the presentation?
